西利宾胺预防抗结核药物肝损害的临床观察

The clinical study on preventing medicamentous liver lesion induced by antituberculosis drugs of silybin meglumine tablebs

目的 探讨西利宾胺对初治菌阳肺结核患者抗结核药物肝损害的预防效果。方法 2 4 2例初治菌阳肺结核分为观察组和对照组 ,均应用“2HRZS(E) / 4HR”方案抗结核化疗 ,观察组加用西利宾胺 ,对照组加肝泰乐。结果 观察组药物性肝损害发生率为 6 . 6 % ;中断抗结核化疗为 4 1% ;调整化疗方案为 1 6 % ;与对照组的 19. 2 %、14. 2 %、9. 2 %比较 ,均有显著性差异 (P <0 . 0 1)。结论 西利宾胺可显著降低初治菌阳肺结核患者抗结核药物肝损害的发生率 ,减少因抗结核药所致肝损害而造成的不规则化疗。

objective To study the preventive efficacy of Silybin meglumine tablets on medicamentous liver lesion by antituberculosis drugs. Methods 242 sputum positive initial treated pulmonary tuberculosis were divided into two groups, study group and control group randomly,which were both treated by chemotherapy regimen of 2HRZS(E)/4HR.The study group also took TSM. Results In the study group the morbidity of medicamentous liver lesion was 6 6%,the incidence rate of interrupting treatment was 4 1%,1 6%of cases adjusted the antituberculosis regemen. And the control group was 19 2%,14 2% and 19 2% respectively.There were very significant difference between the two groups( P <0 01).Conclusion Silybin Meglumine tablets can obviously decrease the incidence rate of liver damage of sputum positive initial treated patients induced by antituberculosis drugs and decrease or prevent the irregular chemotherapy that results from the liver damage caused by antituberculosis drugs.